14 results
20-F
2022 FY
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Aug 22
Annual report (foreign)
4:20pm
are seeking to build upon our existing R&D to develop a pipeline of T-Cell testing IVD kits and medical devices that are effective in the diagnosis … for operations was mainly due to increased losses as the Group increased marketing and R&D costs associated with developing our Virax brands during the year
424B4
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
21 Jul 22
Prospectus supplement with pricing info
10:01am
and development of new products and services, which may not be successful.
We are seeking to build upon our existing R&D to develop a pipeline of T-Cell testing … associated with the arbitration mentioned above offset by increased marketing and R&D costs associated with developing our Virax brands during
FWP
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
30 Jun 22
Free writing prospectus
9:04pm
are burdened with investing into multiple business segments which compete internally for R&D dollars and growth channels. Virax is focused
FWP
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
30 Jun 22
Free writing prospectus
1:29pm
are burdened with investing into multiple business segments which compete internally for R&D dollars and growth channels. Virax is focused
F-1/A
wjmtjt2p
24 Jun 22
Registration statement (foreign) (amended)
9:47pm
F-1/A
cf8vjw3
24 Jun 22
Registration statement (foreign) (amended)
8:21am
F-1/A
p30xnv2e ndyd7zto9
21 Jun 22
Registration statement (foreign) (amended)
6:26am
F-1/A
4ecmeb0i23n g3v
6 Jun 22
Registration statement (foreign) (amended)
6:13pm
F-1/A
ktn5rl
11 May 22
Registration statement (foreign) (amended)
3:11pm
F-1/A
38r8ko2wsdbs2ebr 73
22 Apr 22
Registration statement (foreign) (amended)
6:09pm
F-1
aofi0t
18 Mar 22
Registration statement (foreign)
3:50pm
DRS/A
w34y6k d8uuekfl
17 Feb 22
Draft registration statement (amended)
12:00am
DRS
hvnwcfi7a1o4b
27 Dec 21
Draft registration statement
12:00am
- Prev
- 1
- Next